SCHEMBL10054296

SCHEMBL10054296

CC(C)(O)c1ccccc1CCC(SCC1(CC(=O)O)CC1)c1cccc(CCc2ccc3ccc(Cl)cc3n2)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYSLTR1 Q9Y271 12/20 0.73
▸ CYSLTR2 Q9NS75 11/20 0.73
▸ CYP2C8 P10632 2/20 0.73
▸ MEN1 O00255 1/20 0.73
▸ RECQL P46063 1/20 0.73
▸ BLM P54132 1/20 0.73
▸ KMT2A Q03164 1/20 0.73
▸ ABCB11 O95342 1/20 0.73
▸ EGFR P00533 1/20 0.73
▸ ESR1 P03372 1/20 0.73
▸ NR3C1 P04150 1/20 0.73
▸ FYN P06241 1/20 0.73
▸ PGR P06401 1/20 0.73
▸ ADRB2 P07550 1/20 0.73
▸ ADRB1 P08588 1/20 0.73
▸ ADRA2A P08913 1/20 0.73
▸ ADORA3 P0DMS8 1/20 0.73
▸ CHRM1 P11229 1/20 0.73
▸ ADRB3 P13945 1/20 0.73
▸ ADRA2B P18089 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8931783 1.00 CYSLTR1 (0.73) CYSLTR1CYSLTR2CYP2C8MEN1RECQL
SCHEMBL17195070 0.91 CYSLTR1 (0.75) CYSLTR1CYSLTR2CYP2C8MEN1RECQL
SCHEMBL1204507 0.91 CYSLTR1 (0.75) CYSLTR1CYSLTR2CYP2C8MEN1RECQL
SCHEMBL1204603 0.91 CYSLTR1 (0.75) CYSLTR1CYSLTR2CYP2C8MEN1RECQL
SCHEMBL12882800 0.91 CYSLTR1 (0.75) CYSLTR1CYSLTR2CYP2C8MEN1RECQL
SCHEMBL10054298 0.91 CYSLTR1 (0.75) CYSLTR1CYSLTR2CYP2C8MEN1RECQL
SCHEMBL9690128 0.89 CYSLTR1 (0.59) CYSLTR1CYSLTR2CYP2C8MEN1RECQL
SCHEMBL9689591 0.88 CYSLTR2 (0.56) CYSLTR1CYSLTR2CYP2C8MEN1RECQL
SCHEMBL10020805 0.87 CYSLTR1 (0.81) CYSLTR1CYSLTR2CYP2C8MEN1RECQL
SCHEMBL9222120 0.86 CYSLTR2 (0.55) CYSLTR1CYSLTR2CYP2C8MEN1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115004-B2 Process for pure montelukast sodium through pure intermediates as well as amine salts MSN LABORATORIES LIMITED (IN) 2012-02-14 — — US disclosed
US-20100056793-A1 PROCESS FOR PURE MONTELUKAST SODIUM THROUGH PURE INTERMEDIATES AS WELL AS NOVEL AMINE SALTS MSN LABORATORIES LIMITED (IN) 2010-03-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056793-A1 PROCESS FOR PURE MONTELUKAST SODIUM THROUGH PURE INTERMEDIATES AS WELL AS NOVEL AMINE SALTS LTC4S, CMA1, CYSLTR2 CYSLTR1 4/4885CYSLTR2 3/4885CYP2C8 1075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback